Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NAALADL2 antisense RNA 1 (NAALADL2-AS1)
- Target
- NAALADL2-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
NAALADL2 antisense RNA 1 (NAALADL2-AS1) is a long non-coding RNA gene located on chromosome 3 in humans. It is transcribed antisense to the large NAALADL2 protein-coding gene, which itself is implicated in cancer biology and cell adhesion mechanisms through its extensive copy number variation and transcriptional regulation. The specific biological function, clinical relevance, and molecular interactions of NAALADL2-AS1 have not been defined in the current scientific literature. Unlike its protein-coding partner or other antisense RNAs in the region (such as NAALADL2-AS2), NAALADL2-AS1 has not been validated as a therapeutic target, disease biomarker, or drug interaction partner. Its role, if any, may be regulatory, typical of lncRNAs, but further research is needed to clarify its biological and clinical significance.
- Other names
- NAALADL2 Antisense RNA 1NAALADL2-AS1
02
Mechanism of action
No mechanism of action for drugs targeting NAALADL2-AS1 is documented. Synthetic antisense or RNAi techniques targeting related genes are described in patents, but not for NAALADL2-AS1 specifically.
03
Biological functions
UnknownNo experimentally validated biological function is documented for NAALADL2-AS1. Due to its antisense orientation, it may regulate transcription, splicing, or stability of the NAALADL2 mRNA (inference based on lncRNA biology).
04
Disease associations
OtherDirect associations of NAALADL2-AS1 with disease are not well described in the literature. Most disease relevance for the region is attributed to NAALADL2 protein and other antisense transcripts, such as NAALADL2-AS2, which has been studied for roles in prostate cancer. NAALADL2 copy number or expression changes have correlative roles in cancer, but not specifically NAALADL2-AS1.
05
Safety considerations
None
06
Interacting drugs
None
07
Biomarkers
None
Beyond the preview
Go deeper on NAALADL2 antisense RNA 1 (NAALADL2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAALADL2 antisense RNA 1 (NAALADL2-AS1).